Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from NKGen Biotech ( (NKGN) ) is now available.
On April 15, 2026, NKGen Biotech and its subsidiary entered into a $39.9 million secured convertible loan agreement with AlpineBrook Capital that refinances multiple existing debts and provides $350,000 in new cash, bearing 12% interest and maturing in one year. The loan is convertible into common stock at $0.08 per share, is secured by first-priority liens over most of the company’s personal and intellectual property assets and a pledge of its 65% stake in NKGen Korea, and restricts prepayment and certain corporate actions.
As part of the financing, NKGen agreed to issue AlpineBrook up to 11.8 million additional shares as consideration, a warrant to purchase further shares at $0.08, and extensive investor rights including registration rights, the ability to designate up to five board members, broad protective and preemptive rights, and a right of first refusal over any sale of NKGen Korea stock. The board simultaneously amended the bylaws to cap the board size at nine directors, underscoring a material shift in governance and control dynamics as the lender gains significant influence over future financings, strategic decisions, and potential dilution for existing shareholders.
More about NKGen Biotech
NKGen Biotech, Inc. is a Delaware-based biotechnology company focused on developing immunotherapy treatments, with operations that include a majority stake in NKGen Biotech Korea Co., Ltd. The company currently has a limited cash balance and is actively seeking additional funding to support its business operations and working capital needs.
Average Trading Volume: 4,743
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.